

U.S. Appl. Ser. No.: 10/054,638
Preliminary Amendment

Please Rewrite The Pending Claims

Claims 1-17 (Previously Cancelled).

18. (Presently amended) An immunological composition comprising two, three, or four distinct protein-polysaccharide conjugates, wherein each of the conjugates comprises a purified capsular polysaccharide derived from a serogroup of *N. meningitidis* conjugated to ~~one or~~ more a carrier protein ~~protein(s)~~, wherein at least one serogroup is W-135 or Y.

19. (Presently amended) The immunological composition of claim 18, wherein at least one of the capsular polysaccharides is from *N. meningitidis* serogroup A or C.

20. (Presently amended) The immunological composition of claim 19, wherein at least one of the capsular polysaccharides is from *N. meningitidis* serogroup A.

21. (Presently amended) The immunological composition of claim 19, wherein at least one of the capsular polysaccharides is from *N. meningitidis* serogroup C.

22. (Presently amended) The immunological composition of claim 18, comprising two distinct protein-polysaccharide conjugates, wherein a first conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup W-135 and a second conjugate comprises a purified capsular polysaccharide selected from the group consisting of *N. meningitidis* serogroups ~~serogroup~~ Y, A or C.

23. (Presently amended) The immunological composition of claim 22, wherein the second conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup Y.

24. (Presently amended) The immunological composition of claim 22, wherein the second conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup A.

25. (Presently amended) The immunological composition of claim 22, wherein the second conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup C.

U.S. Appl. Ser. No.: 10/054,638
Preliminary Amendment

26. (Presently amended) The immunological composition of claim 18, comprising two distinct purified protein-polysaccharide conjugates, wherein a first conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup Y and a second conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroups serogroup A or C.

27. (Presently amended) The immunological composition of claim 26, wherein the second conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup A.

28. (Presently amended) The immunological composition of claim 26, wherein the second conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup C.

29. (Presently amended) The immunological composition of claim 18, comprising three distinct protein-polysaccharide conjugates, wherein a first conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup W-135 and a second conjugate ~~comprises~~ comprising a purified *N. meningitidis* capsular polysaccharide selected from the group consisting of Y, A and C and a third conjugate ~~comprises~~ comprising a purified *N. meningitidis* capsular polysaccharide selected from the group consisting of serogroup Y, A and C, wherein the second conjugate is different from the third conjugate.

30. (Presently amended) The immunological composition of claim 29, wherein at least one of the second conjugate and the third conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup Y.

31. (Presently amended) The immunological composition of claim 29, wherein at least one of the second conjugate and the third conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup A.

32. (Presently amended) The immunological composition of claim 29, wherein at least one of the second conjugate and the third conjugate comprises a purified capsular polysaccharide of *N. meningitidis* serogroup C.

33. (Presently amended) The immunological composition of claim 18, comprising four distinct protein-polysaccharide conjugates, wherein a first conjugate comprises a purified *N. meningitidis* capsular

U.S. Appl. Ser. No.: 10/054,638
Preliminary Amendment

polysaccharide of serogroup W-135, a second conjugate comprises a purified *N. meningitidis* capsular polysaccharide of serogroup Y, a third conjugate comprises a purified *N. meningitidis* capsular polysaccharide of serogroup A, and a fourth conjugate comprises a purified *N. meningitidis* capsular polysaccharide of serogroup C.

34. (New) The immunological composition of claim 18 further comprising an adjuvant.

35. (New) The immunological composition of claim 34, wherein said adjuvant is selected from the group consisting of aluminum adjuvants, Freund's adjuvant, BAY, DC-chol, pcpp, monophosphoryl lipid A, CpG, QS-21, cholera toxin, and formyl methionyl peptide.

36. (New) The immunological composition of claim 35, wherein said aluminum adjuvant is aluminum hydroxide.

37. (New) The immunological composition of claim 35, wherein said aluminum adjuvant is aluminum phosphate.

38. (New) The immunological composition of claim 33, wherein 0.5ml of said immunological composition comprises from about 0.02 μ g to about 5 μ g of said purified *N. meningitidis* capsular polysaccharide A conjugated to about 30 to 60 μ g of carrier protein.

39. (New) The immunological composition of claim 38, comprising 4 μ g of purified *N. meningitidis* serogroup A capsular polysaccharide conjugated to about 48 μ g of carrier protein.

40. (New) The immunological composition of claim 33, wherein 0.5ml of said immunological composition comprises from about 0.02 μ g to about 5 μ g of said purified *N. meningitidis* capsular polysaccharide C conjugated to about 30 to 60 μ g of carrier protein.

41. (New) The immunological composition of claim 40, comprising 4 μ g of purified *N. meningitidis* serogroup C capsular polysaccharide conjugated to about 48 μ g of carrier protein.

U.S. Appl. Ser. No.: 10/054,638
Preliminary Amendment

42. (New) The immunological composition of claim 33, wherein 0.5ml of said immunological composition comprises from about 0.02 μ g to about 5 μ g of said purified *N. meningitidis* capsular polysaccharide W-135 conjugated to about 30 to 60 μ g of carrier protein.

43. (New) The immunological composition of claim 42, comprising 4 μ g of purified *N. meningitidis* serogroup W-135 capsular polysaccharide conjugated to about 48 μ g of carrier protein.

44. (New) The immunological composition of claim 33, wherein 0.5ml of said immunogenic composition comprises from about 0.02 μ g to about 5 μ g of said purified *N. meningitidis* capsular polysaccharide Y conjugated to about 30 to 60 μ g of carrier protein.

45. (New) The immunological composition of claim 44, comprising 4 μ g of purified *N. meningitidis* serogroup Y capsular polysaccharide conjugated to about 48 μ g of carrier protein.

46. (New) The immunological composition of claim 34, wherein said carrier protein is a single protein species.

47. (New) The immunological composition of claim 46, wherein said carrier protein species comprises an inactivated bacterial toxin.

48. (New) The immunological composition of claim 47, wherein said inactivated bacterial toxin is derived from an organism selected from the group consisting of *Corynebacteria diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, *Pseudomonas aeruginosa*, and *Escherichia coli*.

49. (New) The immunological composition of claim 48, wherein said inactivated bacterial toxin is derived from *Corynebacteria diphtheriae*.

50. (New) The immunological composition of claim 49, wherein said inactivated bacterial toxin derived from *Corynebacteria diphtheriae* is CRM197.

51. (New) The immunological composition of claim 33 formulated as a sterile liquid.

U.S. Appl. Ser. No.: 10/054,638
Preliminary Amendment

52. (New) The immunological composition of claim 51, wherein said sterile liquid is contained within in a single use syringe.

53. (New) The immunological composition 52, wherein said syringe is packaged in a box with instructions for administration of said composition.

54. (New) The immunological composition of claim 51, wherein said sterile liquid is contained within a vial.

55. (New) The immunological composition of claim 54, wherein said vial is packaged in a box with instructions for administration of said composition.

56. (New) The immunological composition of claim 33, further comprising a pharmaceutically acceptable preservative.

57. (New) The immunological composition of claim 56, wherein said pharmaceutically acceptable preservative is selected from the list consisting of benzyl alcohol, parabens, thimerosal, chlorobutanol, and benzalkonium chloride.